pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The post Takeda grows in gene therapies again with $2bn Code Bio deal appeared first on. Last October it signed a $3.6

Gene Therapy 100

Gene Therapy Gene Gene Sequencing Immune Response 100

pharmaphorum

APRIL 16, 2021

The 2 nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate. Join your peers online and discover: How Chameleon Bioscience are developing an immune evasive AAV for repeat dosing.

Gene Therapy 52

Gene Therapy Gene Immune Response Antibody 52

pharmaphorum

FEBRUARY 8, 2022

With the safety of gene therapies thrown into the spotlight by a series of FDA clinical holds, Astellas has said that an interim readout in a phase 1/2 trial of its Pompe disease candidate AT845 hasn’t found any cause for concern. The post Astellas says Pompe gene therapy clears safety hurdle appeared first on.

Gene Therapy 52

Gene Therapy Gene Immune Response Licensing 52

XTalks

MARCH 13, 2023

The US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) held a recent town hall where three experts from the regulator provided guidance on how to design and conduct gene therapy clinical trials for rare diseases. It’s a very exciting time in gene therapy.

Gene Therapy 52

Gene Therapy Clinical Trials Clinical Trials Gene 52

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

JANUARY 18, 2021

Use of AAVnerGene capsid library provided to Neurophth for ophthalmic gene therapy. Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. WUHAN, China and NEWARK, DE. ,

Gene Therapy 52

Gene Therapy Gene Immune Response Manufacturing 52

Pharmaceutical Technology

JUNE 21, 2023

GEMCOVAC-OM was developed using indigenous platform technology. The vaccine produced significantly higher immune responses when given as a booster. Clinical findings had showed the need to develop variant-specific vaccines. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Immune Response 130

Immune Response Vaccination Vaccine Gene Therapy 130

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

Pharmaceutical Technology

JULY 5, 2022

Furthermore, equity holders of TeneoTwo are entitled to get up to $805m in research and development (R&D)-based milestone payments as well as up to $360m as commercial-related milestone payments from AstraZeneca. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Immune Response 147

Immune Response Gene Therapy Gene Development 147

Pharmaceutical Technology

MAY 24, 2023

“Our board and management team believe that the combined company will be well-positioned to develop powerful new therapies with the potential to overcome resistance to current immunotherapies, an area of significant unmet need.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

Delveinsight

DECEMBER 22, 2020

FDA Puts uniQure’s Hemophilia B Gene Therapy on Leash. In a recent, uniQure faced backlash after its hemophilia B gene therapy got hit with clinical hold by the USFDA. . The Hemophilia B market has several therapies, however, no therapy has been able to kill the disease from its root.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

The Pharma Data

JANUARY 17, 2021

LONDON–( BUSINESS WIRE )– Ixaka Ltd , an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies (MCTs) and targeted nanoparticle (TNP) therapeutics.

Gene Therapy 40

Gene Therapy Gene In-Vivo Genetics 40

Drug Discovery World

MARCH 19, 2024

Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprogrammes tumour cells into antigen-presenting dendritic cells, ultimately leading to a personalised anti-tumour immune response.

In-Vivo 52

In-Vivo Gene Therapy Immune Response Packaging 52

Pharmaceutical Technology

DECEMBER 1, 2022

A clinical-stage biopharmaceutical firm, Liminatus focuses on the development of new therapies for cancer that utilises the immune system of the body to detect and fight cancer cells. It can induce immune responses against Guanylyl Cyclase C (GCC) expressing colorectal, pancreatic, gastric and oesophageal cancers.

Gene Therapy 130

Gene Therapy Clinical Trials Clinical Trials Immune Response 130

pharmaphorum

NOVEMBER 30, 2020

Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies. This is particularly pertinent in rare diseases, as a number of gene therapy products use viral delivery methods to deliver the transgene to target organs.

Gene Therapy 103

Gene Therapy Gene Antibody Clinical Trials 103

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The gene therapy-based vaccine targets mucosal tissues in the gastrointestinal tract, allowing for greater selectivity and targeted delivery compared to traditional vaccines.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Roots Analysis

MAY 21, 2024

Amidst the ongoing initiatives to develop therapeutic interventions with improved bioavailability, lipid nanoparticle (LNPs) have specifically attracted the attention of researchers and drug developers. Further, they have been extensively utilized in the development of mRNA vaccines for COVID-19.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. We have been very impressed by their vision and the relevance of their platform.”.

Genome 96

Genome Genomics Medicine Development 96

Delveinsight

DECEMBER 3, 2020

The company anticipates the test can aid in tracking the success of vaccines and recognize people who have recovered from infection and could serve as convalescent plasma donors or help in the development of new therapies. Janssen buys a gene therapy asset. Zimmer Biomet buys chest surgery toolmaker A&E Medical.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

MARCH 12, 2024

Elicera Therapeutics will make parts of its technology iTANK available to a medical oncologist and researcher at the undisclosed US cancer centre, whose investigation focuses on the development of novel immunotherapies. The iTANK technology platform has been developed for arming and enhancing CAR T-cells for the treatment of solid tumours.

Immune Response 52

Immune Response Gene Therapy Licensing Licensing 52

pharmaphorum

JULY 26, 2022

Fortunately, since the emergence of the first treatment in 1987 and the development of effective countermeasures, the condition is no longer a terminal one. It is hoped that the vaccine would help the immune system recognise the virus upon infection and allow the body to more effectively combat its propagation through the body.

Gene Therapy 139

Gene Therapy Protein Vaccination Vaccine 139

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

APRIL 12, 2023

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. The development of organoids and spheroids over a decade ago has helped to bridge the gap. OOC systems represent the next generation platform for predicting drug effects in humans.

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

JANUARY 20, 2023

This paid-for advertorial by CN Bio appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Despite advancements, the drug development process remains inefficient. The development of organoids and spheroids over a decade ago has helped to bridge the gap. References DOI: 10.1016/j.apsb.2022.02.002

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. What makes an ideal AAV analytics tool for process development?

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Delveinsight

AUGUST 26, 2021

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion. Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

JUNE 28, 2022

million in possible milestone payments apiece for up to three development programmes based on Sutro’s immunostimulatory antibody-drug conjugate (iADC) technology. The three programmes are focusing on so-called “cold” tumours – in other words those that have little infiltration by immune system cells.

Antibody 98

Antibody Immune Response Gene Therapy Drugs 98

Drug Discovery World

APRIL 5, 2023

The partnership is focused on evaluating Akamis Bio’s lead compound – NG-350G – an immuno-stimulatory tumour gene therapy that could work as part of combination therapies to treat pancreatic cancer. DDW: What have been some of the challenges so far in developing therapies for pancreatic cancer?

Gene Therapy 52

Gene Therapy Gene Immune Response Development 52

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression. Challenges and Future Directions: Despite their immense promise, biologics are not without challenges.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. Even before this, however, Amsterdam was established as an important centre for drug development. The CDD will sponsor and manage KWF-supported trials.

Drugs 59

Drugs Life Science Gene Editing Gene 59

Drug Discovery World

MAY 11, 2023

Kerstin Pohl , Senior Global Marketing Manager, Gene Therapy & Nucleic Acid at SCIEX, looks at the application of liquid chromatography-mass spectrometry for analysing host cell proteins. Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases.

Production 52

Production Gene Protein Vaccination 52

pharmaphorum

NOVEMBER 2, 2022

billion on offer in milestones if the programmes meet development and commercial objectives. According to a statement from the two companies, Arcturus will contribute its STARR self-amplifying mRNA vaccine and LUNAR lipid nanoparticle delivery platform, which has already been deployed in the development of COVID-19 vaccine ARCT-154.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52

Pharmaceutical Technology

APRIL 24, 2023

In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. Langer’s engineering lab was instrumental in the development of these lipid nanoparticles, playing into his role in co-founding Moderna.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

Delveinsight

SEPTEMBER 23, 2021

Backed by founding investor Versant Ventures, 858 Therapeutics will develop a pipeline of oncology therapeutics based on RNA technology with the new funds. Gotham, which also counts Versant as an early investor, is developing small-molecule inhibitors of mRNA-modifying proteins for cancer. Stafford and co. Jay Bradner, M.D.,

RNA 61

RNA Gene Therapy Gene Protein 61

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Here are 5 considerations when developing a communications strategy for a novel genetic medicine. #1.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52